Adelphi Real World

Author Of 1 Presentation

Observational Studies Poster Presentation

P0922 - The positive impact of dimethyl fumarate and patient services to address relapsing-remitting multiple sclerosis patients’ unmet medical needs (ID 1290)

Speakers
Presentation Number
P0922
Presentation Topic
Observational Studies

Abstract

Background

Biogen Patient Support Programmes (PSP) are designed to address unmet medical needs (education, compliance to therapy, disease management) of patients on treatment with Multiple Sclerosis (MS) disease modifying treatments. The combination of lifesaving drugs and meaningful services could lead to an overall improvement of health outcomes. For the scope of this pilot analysis, UK and German relapsing-remitting MS (RRMS) patients receiving dimethyl fumarate (DMF) have been included.

Objectives

To compare healthcare resource use (HRU), work productivity and activity impairment (WPAI), and quality of life (QoL) outcomes for RRMS patients receiving DMF and enrolled on a PSP for at least 12 months vs. DMF patients not on a PSP (Non-PSP).

Methods

Pilot analysis was conducted using data from the Adelphi MS Disease Specific Programme, a cross-sectional survey of neurologists and MS patients in the UK and Germany between March and September 2019. Propensity score matching on age, gender, EDSS at current DMT initiation, number of lines of therapy, current DMF duration, country and MS nurse involvement in the last 12 months was used to create balanced groups. HRU, WPAI, and QoL were compared between groups.

Results

Among 232 DMF patients, 83 were on a PSP and 149 were Non-PSP. DMF PSP patients reported significantly fewer hospitalizations in the last 12 months overall (0.00 vs 0.06, p=0.020). PSP patients also reported significantly less work impairment due to problem according to the WPAI (18.28% vs 24.05%, p=0.017). PSP patients reported significantly higher EQ-5D scores overall (0.91 vs 0.86, p=0.046). Significantly lower MSIS-29 scores were also reported for PSP patients; patients were less bothered by problems sleeping (1.64 vs 2.18, p<0.001) and lack of confidence (1.53 vs 1.82, p=0.047).

Conclusions

Enrolment on the DMF PSP is associated with reduced burden to the UK and German healthcare systems, providing scope for allocation of resources elsewhere. There was also a reduction in patient’s WPAI and a higher level of QoL for those enrolled on the DMF PSP. These pilot results suggest there may be value in further detailed research to validate the signals seen in this cross-sectional approach.

Study Supported by: Biogen

Collapse